DiaMedica Therapeutics Inc. (NASDAQ:DMAC - Get Free Report) saw a significant decrease in short interest during the month of November. As of November 30th, there was short interest totalling 151,500 shares, a decrease of 12.2% from the November 15th total of 172,500 shares. Based on an average daily trading volume, of 83,100 shares, the days-to-cover ratio is presently 1.8 days.
Analysts Set New Price Targets
Separately, HC Wainwright reiterated a "buy" rating and issued a $7.00 target price on shares of DiaMedica Therapeutics in a report on Friday, November 15th.
View Our Latest Analysis on DMAC
Hedge Funds Weigh In On DiaMedica Therapeutics
Several institutional investors have recently added to or reduced their stakes in the stock. Geode Capital Management LLC raised its stake in shares of DiaMedica Therapeutics by 29.6% during the 3rd quarter. Geode Capital Management LLC now owns 306,958 shares of the company's stock worth $1,286,000 after buying an additional 70,070 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of DiaMedica Therapeutics in the 3rd quarter worth about $40,000. Blue Trust Inc. acquired a new stake in DiaMedica Therapeutics in the 3rd quarter valued at about $185,000. Magnolia Capital Advisors LLC purchased a new position in DiaMedica Therapeutics during the 2nd quarter valued at about $87,000. Finally, Vanguard Group Inc. raised its position in DiaMedica Therapeutics by 26.3% during the first quarter. Vanguard Group Inc. now owns 1,013,522 shares of the company's stock worth $2,807,000 after acquiring an additional 211,351 shares during the last quarter. Institutional investors and hedge funds own 10.12% of the company's stock.
DiaMedica Therapeutics Price Performance
Shares of DMAC stock traded down $0.26 during trading hours on Friday, hitting $5.38. The stock had a trading volume of 86,668 shares, compared to its average volume of 58,901. The firm has a market capitalization of $230.05 million, a PE ratio of -9.61 and a beta of 1.51. DiaMedica Therapeutics has a twelve month low of $2.14 and a twelve month high of $5.74. The stock's 50 day moving average is $4.62 and its 200 day moving average is $3.85.
DiaMedica Therapeutics Company Profile
(
Get Free Report)
DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider DiaMedica Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DiaMedica Therapeutics wasn't on the list.
While DiaMedica Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
